Plain-English translation of NCT03853733 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is studying a specific radiation therapy approach for people with advanced rectal cancer who are not able to have surgery. Researchers are measuring how well this treatment — called hypofractionated palliative radiotherapy — helps relieve symptoms like bleeding and pain, and how well patients tolerate the side effects.
Many patients with advanced rectal cancer cannot have surgery due to their age, other health conditions, or cancer that has spread to multiple places in the body. This trial exists to find the best way to use radiation therapy to provide comfort and relief of symptoms for these patients, rather than trying to cure the cancer.
You likely qualify if…
You likely don't qualify if…
You would come to the hospital or radiation center for 13 radiation therapy sessions over about 17 days. Before each treatment, you would follow simple preparation steps like emptying your bladder and drinking water to help protect healthy tissue. Researchers would measure how your symptoms — especially bleeding and pain — improve after treatment ends, and track any side effects you experience.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Spain
Sponsor
Consorci Sanitari de Terrassa
Enrollment target
~50 participants
Started
October 2016
Primary completion
March 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Joan Lozano, MD
Consorci Sanitari de Terrassa
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.